# US 2023/0266322 A1 · Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0266322 A1
- Document ID: US20230266322A1
- Status: Published application
- Kind: A1
- Application number: 18/003,999
- Filed: 2021-06-28
- Published: 2023-08-24
- Earliest claimed: 2020-06-30
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Assistance Publique-HôPitaux De Paris (Aphp); Sorbonne Universite; Université Paris Cité
- Applicants: Inserm (Institut National De La Santé Et De La Recherche MéDicale); Assistance Publique-HôPitaux De Paris (Aphp); Sorbonne Université; Université Paris Cité
- Inventors: Franck PAGES; Jérôme GALON; Guy ZEITOUN; Amos KIRILOVSKY
- Web page: https://patentgrep.com/patent/US20230266322A1

## CPC

- G01N 33/575: for cancer
- G01N 2800/54: Determining the risk of relapse
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The inventors assessed in locally advanced rectal cancer whether a diagnostic biopsy-adapted Immunoscore (ISB) could predict response to neoadjuvant treatment (nT) and better define patients eligible to a postoperative adjuvant therapy. The inventors showed that ISB was an independent parameter, more informative than pre- (P<0.001) and post-nT (P<0.05) imaging to predict disease-free survival. ISB combined pathological response discriminated very poor responders that could benefit of a postoperative adjuvant therapy. Accordingly, the present invention relates to methods for predicting the recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery.

## Claims

### Claim 1

A method of predicting the risk of recurrence and/or death of a patient suffering from a solid cancer after preoperative adjuvant therapy and radical surgery and treating the patient, comprising
assessing at least two parameters, wherein the first parameter is an immune response determined before the preoperative adjuvant therapy and the second parameter is a pathological response determined after radical surgery and wherein the combination of said parameters indicates the risk of recurrence and/or death and
administering a postoperative adjuvant therapy to the patient determined to have a high risk of recurrence and/or death, based on the step of assessing.

### Claim 2 (depends on 1)

The method of claim 1 wherein the patient suffers from a primary cancer or from a metastatic cancer.

### Claim 3 (depends on 1)

The method of claim 1 wherein the patient suffers from a locally advanced cancer.

### Claim 4 (depends on 1)

The method of claim 1 wherein the patient suffers from a locally advanced rectal cancer.

### Claim 5 (depends on 1)

The method of claim 1 wherein the preoperative adjuvant therapy comprises a radiotherapy, a chemotherapy, a targeted therapy, a hormone therapy, an immunotherapy or a combination thereof.

### Claim 6 (depends on 1)

The method of claim 1 wherein the preoperative adjuvant therapy comprises a combination of radiotherapy and chemotherapy.

### Claim 7 (depends on 1)

The method of claim 1 wherein the immune response is assessed by quantifying one or more immune markers determined in a tumor biopsy sample obtained from the patient before the preoperative adjuvant chemotherapy.

### Claim 8 (depends on 7)

The method of claim 7 wherein the one or more immune markers comprise the density of CD3+ cells, the density of CD8+ cells, the density of CD45RO+ cells, the density of GZM-B+ cells, the density of CD103+ cells and/or the density of B cells.

### Claim 9 (depends on 8)

The method of claim 8 wherein the one or more immune markers comprise the density of CD3+ cells and the density of CD8+ cells, the density of CD3+ cells and the density of CD45RO+ cells, the density of CD3+ cells the density of GZM-B+ cells, the density of CD8+ cells and the density of CD45RO+ cells, the density of CD8+ cells and the density of GZM-B+ cells; the density of CD45RO+ cells and the density of GZM-B+ cells or the density of CD3+ cells and the density of CD103+ cells.

### Claim 10 (depends on 9)

The method of claim 9 wherein the density of CD3+ cells and the density of CD8+ cells is determined in the tumor biopsy sample.

### Claim 11 (depends on 7)

The method of claim 7 wherein the one or more immune markers comprise the expression level of one or more genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21.

### Claim 12 (depends on 7)

The method of claim 7 wherein the one or more immune markers comprise the expression level of one or more genes selected from the group consisting of GZMH, IFNG, CXCL13, GNLY, LAG3, ITGAE, CCL5, CXCL9, PF4, IL17A, TSLP, REN, IHH, PROM1 and VEGFA.

### Claim 13 (depends on 7)

The method according of claim 7 wherein the one or more immune markers comprise an expression level of at least one gene representative of human adaptive immune response and an expression level of at least one gene representative of human immunosuppressive response.

### Claim 14 (depends on 13)

The method of claim 13 wherein the at least one gene representative of human adaptive immune response is selected from the group consisting of CCL5, CCR2, CD247, CD3E, CD3G, CD8A, CX3CL1, CXCL11, GZMA, GZMB, GZMH, GZMK, IFNG, IL15, IRF1, ITGAE, PRF1, STAT1 and TBX21 and said at least one gene representative of human immunosuppressive response is selected from the group consisting of CD274, CTLA4, IHH, IL17A, PDCD1, PF4, PROM1, REN, TIM-3, TSLP, and VEGFA.

### Claim 15 (depends on 7)

The method of claim 7 wherein the immune response is assessed by a scoring system comprising the steps of:
a) quantifying one or more immune markers in a tumor biopsy sample obtained from said patient;
b) comparing each value obtained at step a) for said one or more immune markers with a distribution of values obtained for each of said one or more immune markers from a reference group of patients suffering from said cancer;
c) determining for each value obtained at step a) for said one or more immune markers the percentile of the distribution to which the values obtained at step a) correspond; and
d) calculating the arithmetic mean value or the median value of each percentile determined at step c).

### Claim 16 (depends on 15)

The method of claim 15 wherein the immune response is assessed by a continuous-scoring system that comprises the steps of:
a) quantifying the density of CD3+ cells and the density of CD8+ cells in a tumor biopsy sample obtained from said patient;
b) comparing each density value obtained at step a) with a distribution of values obtained from a reference group of patients suffering from said cancer;
c) determining for each density value obtained at step a) the percentile of the distribution to which the values obtained at step a) correspond; and
d) calculating the arithmetic mean value of each percentile determined at step c).

### Claim 17 (depends on 15)

The method of claim 15 wherein the immune response is assessed by a non-continuous scoring system that comprises the steps of:
a) quantifying the density of CD3+ cells and the density of CD8+ cells in a tumor biopsy sample obtained from said patient;
b) comparing each density value obtained at step a) with a distribution of values obtained from a reference group of patients suffering from said cancer;
c) determining for each density value obtained at step a) the percentile of distribution to which the value corresponds;
d) calculating the arithmetic mean value of each percentile determined in step c);
e) comparing each arithmetic mean value obtained at step d) with a predetermined reference arithmetic mean value of percentile, and
f) assigning a low or high score to each arithmetic mean depending on whether the arithmetic mean value of percentile is respectively lower or higher than the predetermined reference arithmetic mean value of percentile.

### Claim 18 (depends on 15)

The method of claim 15 wherein the immune response is assessed by a non-continuous scoring system that comprises the steps of:
a) quantifying the density of CD3+ cells and the density of CD8+ cells in a tumor biopsy sample obtained from said patient;
b) comparing each density value obtained at step a) with a distribution of values obtained from a reference group of patients suffering from said cancer;
c) determining for each density value obtained at step a) the percentile of the distribution to which the values obtained at step a) correspond;
d) calculating the arithmetic mean value of each percentile determined at step c); and
e) comparing each arithmetic mean value of percentile obtained at step d) with 2 predetermined reference arithmetic mean value percentiles, and
f) assigning a low, intermediate or high score, wherein:
the low score is lower than a lowest predetermined reference arithmetic mean value of percentile,
the intermediate score is comprised between the 2 predetermined reference arithmetic mean values of percentile, and
the high score is higher than a highest predetermined reference arithmetic mean value of percentile.

### Claim 19 (depends on 1)

The method of claim 1 wherein the pathological response is determined by the assessment of the level of ctDNA, by anatomical pathology, by histology and/or histopathology, by a ypTNM scoring system and/or by a tumor regression grading system.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The method of claim 1 wherein the pathological response is assessed by a macroscopic, microscopic, biochemical, immunologic and/or molecular examination of a tumor tissue sample obtained from the patient.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The method of claim 1 wherein the pathological response is assessed by a ypTNM scoring system in combination with a a tumor regression grading system.

### Claim 26 (depends on 1)

The method of claim 1 that comprises, after the step of assessing, the steps of:
b) implementing an algorithm on data comprising the first and second parameters to obtain an algorithm output, the implementing step being computer-implemented; and
c) determining the risk of recurrence and/or death from the algorithm output obtained at step b).

### Claim 27 (depends on 1)

The method of claim 1 wherein when the pathological response is ypTNM=II-IV, and the arithmetic mean or median value of percentile is low, the risk of recurrence and/or death is high, and the survival time of the patient is short, and thus that the patient is eligible for the postoperative adjuvant therapy.

### Claim 28 (depends on 1)

The method of claim 1 wherein the postoperative adjuvant therapy is administered to a patient determined to have a pathological response ypTNM=II-IV and an immune response in which the arithmetic mean or median value of percentile is low.
